Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019

Details for Mechanism ID: 14505
Country/Region: Nigeria
Year: 2017
Main Partner: FHI 360
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $8,755,493 Additional Pipeline Funding: $20,720,888

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $347,135
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $236,170
Care: Pediatric Care and Support (PDCS) $1,759,569
Laboratory Infrastructure (HLAB) $712,164
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Testing: HIV Testing and Counseling (HVCT) $2,456,992
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $2,593,101
Treatment: Pediatric Treatment (PDTX) $650,362
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 3,411
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 1,613
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 3,745
GEND_GBV Number of people receiving post-GBV care 2018 5,358
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 2,663,527
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2018 60,701
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative 2018 1,430
HTS_TST Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative 2018 1,151
HTS_TST Service Delivery Point by Agg Age (Community) Other: <15, Female, Negative 2018 6,504
HTS_TST Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative 2018 5,322
HTS_TST Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Negative 2018 410
HTS_TST Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative 2018 336
HTS_TST Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative 2018 684,887
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative 2018 289
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative 2018 223
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative 2018 14,050
HTS_TST Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative 2018 11,492
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative 2018 68,191
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative 2018 55,788
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative 2018 573,610
HTS_TST Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative 2018 469,311
HTS_TST Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative 2018 1,184
HTS_TST Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative 2018 943
HTS_TST Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative 2018 22,632
HTS_TST Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative 2018 18,496
HTS_TST Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative 2018 1
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative 2018 67,826
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative 2018 55,494
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative 2018 36,269
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative 2018 29,673
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative 2018 148,863
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative 2018 121,799
HTS_TST Sum of Test Result disaggregates 2018 84,549
HTS_TST_POS By Test Result: Positive 2018 84,549
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2018 1,396
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive 2018 501
HTS_TST_POS Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive 2018 360
HTS_TST_POS Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive 2018 65
HTS_TST_POS Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive 2018 55
HTS_TST_POS Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive 2018 27
HTS_TST_POS Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Positive 2018 22
HTS_TST_POS Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive 2018 12,336
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive 2018 18
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive 2018 6
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive 2018 820
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive 2018 645
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive 2018 1,007
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive 2018 755
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive 2018 28,682
HTS_TST_POS Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive 2018 23,445
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive 2018 98
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive 2018 58
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive 2018 2,232
HTS_TST_POS Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive 2018 1,795
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive 2018 3,583
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive 2018 2,939
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive 2018 136
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive 2018 110
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive 2018 1,893
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive 2018 1,548
OVC_SERV Age/Sex: <1 2018 992
OVC_SERV Age/Sex: 1-9 2018 31,618
OVC_SERV Age/Sex: 10-14 Female 2018 9,901
OVC_SERV Age/Sex: 10-14 Male 2018 10,238
OVC_SERV Age/Sex: 15-17 Female 2018 4,698
OVC_SERV Age/Sex: 15-17 Male 2018 4,881
OVC_SERV By: Age/sex: 18-24 Female 2018 1,255
OVC_SERV By: Age/sex: 25+ Female 2018 6,330
OVC_SERV By: Age/sex: Male 18-24 2018 915
OVC_SERV By: Age/sex: Male 25+ 2018 1,112
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2018 71,940
OVC_SERV Program Completion: Active 2018 36,656
OVC_SERV Program Completion: Graduation 2018 35,284
OVC_SERV Sum of Age/Sex disaggregates 2018 29,718
PMTCT_ART Already on ART at beginning of current pregnancy 2018 7,079
PMTCT_ART New on ART 2018 13,773
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 20,852
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 708,048
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 20,895
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 3,838
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 15,445
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 297
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 1,315
PMTCT_STAT By Age (Numerator): Unknown Age 2018 708,048
PMTCT_STAT By Number of known positives: Unknown Age 2018 10,825
PMTCT_STAT By Number of new negative: Unknown Age 2018 684,887
PMTCT_STAT By Number of new positives: Unknown Age 2018 12,336
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 708,048
PMTCT_STAT_den By Age (Denominator): Unknown Age 2018 745,315
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 136
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 1,243
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 353
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 1,819
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 3,799
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 3,551
TB_ART_den Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 149
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 1,371
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 332
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 1,947
TB_PREV By Age/Sex (Numerator): <15, Female 2018 4,041
TB_PREV By Age/Sex (Numerator): <15, Male 2018 3,797
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 95,761
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 41,961
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 145,560
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 145,560
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 207,933
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 5,762
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 5,409
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 136,800
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 59,962
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 207,933
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 382
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 4,027
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 644
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 5,686
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 10,739
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 11,931
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 419
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 4,474
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 708
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 6,330
TX_CURR Aggregated Age/Sex: <15 Female 2018 7,430
TX_CURR Aggregated Age/Sex: <15 Male 2018 6,753
TX_CURR Aggregated Age/Sex: 15+ Female 2018 182,907
TX_CURR Aggregated Age/Sex: 15+ Male 2018 80,338
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 277,428
TX_CURR Sum of Aggregated Age/Sex <15 2018 14,183
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 263,245
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 277,428
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 2,171
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 1,758
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 50,503
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 21,099
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 75,531
TX_NEW Pregnancy status 2018 179
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 75,531
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 263,528
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 237,193
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 5,911
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 638
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 5,619
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 592
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 140,315
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 15,581
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 61,707
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 6,830
TX_PVLS Numerator: Indication: Routine 2018 213,552
TX_PVLS Numerator: Indication: Targeted 2018 23,641
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Routine 2018 6,776
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Targeted 2018 752
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 6,566
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2018 707
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 6,235
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2018 657
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 155,927
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2018 17,319
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 68,544
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2018 7,593
TX_PVLS_den Denominator: Indication: Routine 2018 237,272
TX_PVLS_den Denominator: Indication: Targeted 2018 26,276
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Routine 2018 7,529
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Targeted 2018 837
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 6,540
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 6,215
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 155,665
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 68,503
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 236,923
TX_RET Numerator by Status: Pregnant 2018 7,533
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 263,248
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 7,501
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 7,089
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 172,676
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 75,982
TX_RET_den Denominator by Status: Pregnant 2018 8,367
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 66,324
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 13,273
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 365
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 319
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 8,747
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 3,822
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 1,814
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 1,714
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 43,648
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 19,148
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 16,178
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 1,786
TX_TB_den Denominator: By Screen Result: Negative 2018 46,410
TX_TB_den Denominator: By Screen Result: Positive 2018 19,914
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 17,964
Cross Cutting Budget Categories and Known Amounts Total: $5,267,061
Gender: Gender Equality $158,603
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Promoting gender-related policies and laws that increase legal protection
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Gender: Gender Based Violence (GBV) $1,699,958
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Education $24,040
Renovation $554,700
Food and Nutrition: Commodities $152,217
Economic Strengthening $118,728
Motor Vehicles: Purchased $526,079
Human Resources for Health $2,032,736